- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Magnis Energy Technologies Limited is pleased to announce that Imperium3 New York has completed a valuation on the lithium-ion battery cell facility.
Magnis Energy Technologies Limited [“Magnis” or the “Companr] (ASX:MNS) is pleased to announce that Imperium3 New York [“iM3NY”] has recently completed a valuation on the lithium-ion battery cell manufacturing facility in New York as part of due diligence for project financing. Magnis currently owns over 50% through its direct and indirect ownership in iM3NY and its stake in CLIV.
Independent Valuation
The independent valuation was completed by O’Brien 6- Gere a wholly owned subsidiary of the Ramboll Group. Ramboll Group is based in Denmark and employs over 15,000 engineers globally with over 300 offices in 35 countries.
The valuation began in August 2019 and went through all the items purchased as part of the acquisition made in early 2018. In the current condition of the equipment the report attributes a valuation today of US$71.3L-1 Million [A$105.5 Million]. With Magnis having an ownership of over 50% in iM3NY through its direct and indirect holdings including its stake in CLIV, a value of approximately A$53 Million can be attributed to Magnis’ share in the value of the equipment.
Magnis Managing Director Marc Vogts commented: “We believe that the purchase of the New York battery plant will fast track cell manufacturing at commercial scale for the company once funding for commissioning of the plant is secured. The purchase of the equipment last year was a strategic purchase and today’s announcement validates our decision.”
“We continue to prioritise efforts to secure funding and the third-party valuation of our battery plant will assist in financing considerations.”
Click here to connect with Magnis Energy Technologies (ASX:MNS) for an Investor Presentation.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.